Tata Elxsi and OpenAna Unveil Anatel™, An AI‑Native Platform Redefining Regulatory‑Ready MedTech Software Engineering

Tata Elxsi and OpenAna have jointly launched AnaTel™, an AI‑native software engineering platform for healthcare and MedTech, designed to streamline regulatory compliance and accelerate SaMD development cycles by up to 60%. The debut at DeviceTalks Boston 2026 marks a significant milestone in AI‑driven, regulatory‑ready software delivery for medical technology.

AnaTel™ embeds autonomous AI agents directly into the engineering workflow. Unlike developer productivity tools that focus on code generation alone, AnaTel™ operates across the full AI-Driven Software Delivery Lifecycle, from requirements and architecture through deployment, verification and validation, and continuous optimization, making it a true end-to-end engineering execution platform for regulated environments.

AnaTel™ functions as a configurable AI software team, producing code, documentation, test cases, and compliance artifacts through a specialized Healthcare and Life Sciences agent tailored for MedTech regulatory and engineering demands.

Human engineers and regulatory specialists maintain oversight at every critical review and decision stage. AnaTel™ integrates eSTAR‑aligned submission preparation, requirements traceability matrices, verification and validation records, and audit‑trail documentation directly into daily engineering workflows. By embedding compliance into execution, the platform shortens SaMD (Software as a Medical Device) development and change assessment cycles from eight weeks to just 72 hours, delivering productivity gains of up to 60%.

Key Highlights of AnaTel™

• Launch Context: Introduced at DeviceTalks Boston 2026 by Tata Elxsi and OpenAna
• Purpose: End‑to‑end AI‑native platform for regulated healthcare and MedTech software engineering
• Impact: Cuts SaMD timelines from 8 weeks to 72 hours, with up to 60% productivity gains

Regulatory Drivers

• FDA Draft Guidance (2025): AI‑Enabled Device Software Functions now require lifecycle documentation, traceability, and validation evidence
• Europe’s MDCG 2025‑26: Similar emphasis on rigorous documentation and compliance
• Challenge: Manual assembly of requirements, test cases, and regulatory artifacts across disconnected tools. AnaTel™ embeds compliance into daily workflows, eliminating bottlenecks

Platform Capabilities

• Autonomous AI Agents: Configurable AI software teams generate code, documentation, test cases, and regulatory artifacts
• Healthcare Expert Agent: Fine‑tuned for MedTech regulatory contexts, ensuring contextualized compliance
• Workflow Coverage: Requirements → Architecture → Deployment → Verification/Validation → Continuous Optimization
• Submission Support: eSTAR‑aligned preparation, traceability matrices, audit‑trail documentation

Tata Elxsi’s Role

• Expertise: Decades of experience in regulated medical device environments
• Strengths: Design‑led, AI‑first engineering, ISO 13485 certified Healthcare & Life Sciences practice
• Contribution: Shaped AnaTel™’s reasoning around traceability, validation, and compliance

OpenAna’s Role

• Platform Innovation: Provides Ana, a multi‑agent autonomous engineering system spanning software, security, DevOps, and AI/ML
• Differentiator: Goes beyond coding assistants — full ownership of engineering workflows, with enterprise‑grade guardrails and auditable AI
• Contribution: Embedded autonomous engineering into MedTech’s demanding regulatory domain

Leadership Perspectives

• Sreevatsa Sahasranaman (Tata Elxsi): AnaTel™ accelerates regulatory‑ready engineering while keeping human experts in control
• Rajiv Sondhi (OpenAna): Autonomous AI agents act as reliable co‑engineers in regulated healthcare
• Muthusamy Selvaraj (Tata Elxsi): AnaTel™ exemplifies STEP.UP co‑innovation — accountability for outcomes, not just technology

Strategic Significance

• For Healthcare Teams: Reduces compliance burden, integrates documentation into workflows
• For Regulators: Provides transparent, auditable AI‑driven engineering evidence
• For Industry: Sets a benchmark for AI‑native platforms in regulated environments, bridging speed with safety.